Cargando…

Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort

BACKGROUND AND OBJECTIVE: Early seronegative rheumatoid arthritis (RA) is considered a specific entity, especially regarding diagnostic issues and prognosis. Little is known about its potentially different initial clinical presentation and outcome. We aimed to determine predictors of good response t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lukas, Cédric, Mary, Julia, Debandt, Michel, Daïen, Claire, Morel, Jacques, Cantagrel, Alain, Fautrel, Bruno, Combe, Bernard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858774/ https://www.ncbi.nlm.nih.gov/pubmed/31730497 http://dx.doi.org/10.1186/s13075-019-2020-x

Ejemplares similares

Positive impact on 10-year outcome of the window of opportunity for conventional synthetic DMARDs in rheumatoid arthritis: results from the ESPOIR cohort
por: Kedra, Joanna, et al.
Publicado: (2022)

Outcome of patients with early arthritis without rheumatoid factor and ACPA and predictors of rheumatoid arthritis in the ESPOIR cohort
por: Mouterde, Gaël, et al.
Publicado: (2019)

Osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand as prognostic factors in rheumatoid arthritis: results from the ESPOIR cohort
por: Audo, Rachel, et al.
Publicado: (2015)

Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort
por: Fautrel, Bruno, et al.
Publicado: (2012)

Performance of matrices developed to identify patients with early rheumatoid arthritis with rapid radiographic progression despite methotrexate therapy: an external validation study based on the ESPOIR cohort data
por: Granger, Benjamin, et al.
Publicado: (2016)

Serum Fatty Acid Profiles Are Associated with Disease Activity in Early Rheumatoid Arthritis: Results from the ESPOIR Cohort
por: Sigaux, Johanna, et al.
Publicado: (2022)

Delayed conventional DMARDs therapy is effective in Rheumatoid Arthritis
por: Ahsan, Tasnim, et al.
Publicado: (2017)

Validation of ACR/EULAR definition of remission in rheumatoid arthritis from RA practice: the ESPOIR cohort
por: Zhang, Bin, et al.
Publicado: (2012)

Machine learning predicts response to TNF inhibitors in rheumatoid arthritis: results on the ESPOIR and ABIRISK cohorts
por: Bouget, Vincent, et al.
Publicado: (2022)

Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort
por: Gottenberg, Jacques-Eric, et al.
Publicado: (2009)

DNA Methylation Signatures of Response to Conventional Synthetic and Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis
por: Wang, Susan Siyu, et al.
Publicado: (2023)

Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort
por: Soubrier, M, et al.
Publicado: (2011)

Cytomegalovirus infection: friend or foe in rheumatoid arthritis?
por: Davignon, Jean-Luc, et al.
Publicado: (2021)

Evolution of Direct Costs in the First Years of Rheumatoid Arthritis: Impact of Early versus Late Biologic Initiation - An Economic Analysis Based on the ESPOIR Cohort
por: Chevreul, Karine, et al.
Publicado: (2014)

Sodium excretion is higher in patients with rheumatoid arthritis than in matched controls
por: Marouen, Sarah, et al.
Publicado: (2017)

COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs
por: Tsai, Jih-Jin, et al.
Publicado: (2023)

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
por: Prawjaeng, Juthamas, et al.
Publicado: (2023)

Biologic DMARDs and targeted synthetic DMARDs and the risk of all-cause mortality in rheumatoid arthritis: A systematic review and meta-analysis
por: Pang, Mengduan, et al.
Publicado: (2022)

bDMARD Dose Reduction in Rheumatoid Arthritis: A Narrative Review with Systematic Literature Search
por: Verhoef, Lise M., et al.
Publicado: (2017)

Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies
por: Ferrufino, Cheryl P, et al.
Publicado: (2018)

Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2017)

Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs
por: Strangfeld, A, et al.
Publicado: (2017)

IL-10 Producing B Cells Ability to Induce Regulatory T Cells Is Maintained in Rheumatoid Arthritis
por: Mielle, Julie, et al.
Publicado: (2018)

Multireader assessment as an alternative to reference assessment to improve the detection of radiographic progression in a large longitudinal cohort of rheumatoid arthritis (ESPOIR)
por: Gandjbakhch, Frederique, et al.
Publicado: (2017)

Prediction of sustained biologic and targeted synthetic DMARD-free remission in rheumatoid arthritis patients
por: Burkard, Theresa, et al.
Publicado: (2021)

Espoir pour l’homéopathie française
por: Sarembaud, Alain
Publicado: (2021)

Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies [Corrigendum]
Publicado: (2019)

Efficacy of non-conventional synthetic DMARDs for patients with rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis
por: Yuan, Haoming, et al.
Publicado: (2023)

Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register
por: Redeker, Imke, et al.
Publicado: (2022)

L' espoir : roman
por: Malraux, André, 1901-1976
Publicado: (1937)

High levels of memory B cells are associated with response to a first tumor necrosis factor inhibitor in patients with rheumatoid arthritis in a longitudinal prospective study
por: Daien, Claire I, et al.
Publicado: (2014)

No impact of concomitant methotrexate use on serious adverse event and serious infection risk in patients with rheumatoid arthritis treated with bDMARDs: a systematic literature review and meta-analysis
por: Baradat, Claire, et al.
Publicado: (2017)

Mémoires d'espoir.
por: Gaulle, Charles de, 1890-1970
Publicado: (1970)

Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
por: Mysler, Eduardo, et al.
Publicado: (2021)

HBV and targeted synthetic (ts)DMARDs: what have we learned from bDMARDs and tsDMARDs?
por: Gremese, Elisa, et al.
Publicado: (2020)

Increased Dickkopf-1 in Recent-onset Rheumatoid Arthritis is a New Biomarker of Structural Severity. Data from the ESPOIR Cohort
por: Seror, Raphaèle, et al.
Publicado: (2016)

Patient groups in Rheumatoid arthritis identified by deep learning respond differently to biologic or targeted synthetic DMARDs
por: Kalweit, Maria, et al.
Publicado: (2023)

An Atypical Presentation of Seronegative Rheumatoid Arthritis
por: Ramnauth, Vineeta A, et al.
Publicado: (2023)

Multidrug resistance proteins and DMARD efficacy in rheumatoid arthritis
por: Jansen, G, et al.
Publicado: (2004)

Treatment of Rheumatoid Arthritis with Biologic DMARDS (Rituximab and Etanercept)
por: Gashi, Afrim A., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_7hfp870btt52btaup1u69lcsq0